-
Capital, M&A & Industry Strategy2 weeks ago
Roche finds another oncology gem in Asia with $1.5B B cell disease partnership
Roche has tapped Simcere Zaiming for a new T cell engager that could have broad application in B cell–mediated diseases including lymphoma and autoimmune conditions.
-
Capital, M&A & Industry Strategy2 weeks agoKazia closes oversubscribed offering to fund paxalisib’s clinical development
These proceeds will support the planned and ongoing studies of Kazia’s lead investigational therapy, paxalisib, in triple-negative breast cancer, hormone receptor positive/human epidermal growth factor receptor...
-
Capital, M&A & Industry Strategy2 weeks agoLilly’s deal spree continues with Merida takeout: Deals Report
BIOCENTURY | DEALSLILLY’S DEAL SPREE CONTINUES WITH MERIDA TAKEOUT: DEALS REPORTHaisco, Duality feature in cross-border deals; and more
-
Capital, M&A & Industry Strategy2 weeks ago
Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis
Biomarin has granted Ascendis a non-exclusive, worldwide license to use navepegritide, the active ingredient in the latter company’s recently approved achondroplasia drug Yuviwel, in exchange for...
-
Capital, M&A & Industry Strategy2 weeks agoSocial anxiety drugs have been floundering in the clinic. Could Eli Lilly help tip the scales?
After two notable failures, the social anxiety R&D space gained a major player when Eli Lilly agreed to acquire AtaiBeckley this year.
-
Capital, M&A & Industry Strategy2 weeks agoTeva Pharmaceuticals to acquire BioXcel assets for up to $125m
The agreement arises as part of BioXcel Therapeutics’ voluntary Chapter 11 proceedings in the US Bankruptcy Court for the District of Delaware, initiating a court-supervised sale...
-
Capital, M&A & Industry Strategy2 weeks ago
BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer
Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would be discontinued for futility. The...
-
Capital, M&A & Industry Strategy2 weeks ago
Generate Bio drops as data accidentally leaked ahead of European conference
Phase 1 data from Generate Biomedicines’ ongoing chronic obstructive pulmonary disease study demonstrated “rapid and sustained reductions” across four disease biomarkers.
-
Capital, M&A & Industry Strategy3 weeks ago
Biotech IPOs approach ‘escape velocity’ barring yellow flags that could threaten rebound
Twenty-five biotechs have used the IPO route to go public this year—with five of those debuts occurring this month alone. It’s the most IPOs since 2021,...
-
Capital, M&A & Industry Strategy3 weeks ago
DC judge rejects Merck’s IRA case more than three years after it was filed
After lengthy consideration, a DC federal judge on Monday rejected Merck’s challenge to Medicare drug price negotiations. Judge Colleen Kollar-Kotelly of the US District Court for...
Carbon Dots Emerge as a Powerful Weapon Against Superbugs and Biofilms
Your Zip Code May Shape Your Breast Cancer Tumor’s Genetics and Your Survival Odds
Azithromycin Resistance in Gonorrhea Shifts Genetic Ground, Challenging Molecular Surveillance
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
